Page last updated: 2024-11-04

salmeterol xinafoate and Heart Failure

salmeterol xinafoate has been researched along with Heart Failure in 1 studies

salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Xing, G1
Woo, AY1
Pan, L1
Lin, B1
Cheng, MS1

Reviews

1 review available for salmeterol xinafoate and Heart Failure

ArticleYear
Recent Advances in β
    Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24

    Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Heart Failure; Humans; Muscle

2020